[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shin Kong Wu Ho-Su Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":259},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,76,101,124,155,183,212,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100608884","ultrasound-guided-transcutaneous-pulsed-radiofrequency-for-cervical-radiculopathy-100608884",false,"NCT07207356","Ultrasound Guided Transcutaneous Pulsed Radiofrequency for Cervical Radiculopathy","The Efficacy of Ultrasound Guided Transcutaneous Pulsed Radiofrequency for Cervical Radiculopathy: a Randomized, Sham-controlled, Double-blind Pilot Study","Inclusion Criteria:\n\n* Age between 20 and 75 years old.\n* Clinical diagnosis of cervical radiculopathy, defined by:\n\n  1. Presence of neck pain or paresthesia radiating to the unilateral upper extremity with radicular and dermatomal pattern;\n  2. Positive Spurling's test;\n  3. Positive cervical distraction test\n* Symptoms lasting for over 6 weeks\n* Numeric Rating Scale (NRS) for arm pain ≥ 4 out of 10\n* MRI or CT-confirmed nerve root compression, corresponding to clinical symptoms.\n* Able to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* History of cervical spine surgery.\n* Motor deficit on involving limb\n* Presence of axial neck pain without radicular symptoms\n* Symptoms from shoulder, elbow, or wrist joint or other musculoskeletal co-morbidity such as rheumatologic disease or carpal tunnel syndrome\n* Evidence of serious underlying pathology (e.g., tumor, infection, fracture, or myelopathy)\n* Prior exposure to epidural steroid injection or pulsed radiofrequency therapy within the past 6 months\n* Presence of pregnancy or breastfeeding.\n* History of epilepsy or electronic devices implanted in the body\n* Active infection or skin disease at the stimulator contact site\n* Allergy to electrode patch\n* Unable to understand the study protocol or provide written","ALL","20 Years","75 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cervical radiculopathy (CR) is a painful condition caused by irritation of the cervical nerve roots, often leading to neck, shoulder, and arm pain, sometimes with numbness or weakness. These symptoms can reduce quality of life and place a burden on healthcare systems. Current treatments, such as physical therapy, cervical traction, and medication, are often not fully effective. Pulsed radiofrequency (PRF) has shown benefits for nerve-related pain, but because it requires an invasive procedure, its use is limited.\n\nTranscutaneous pulsed radiofrequency (TCPRF) is a non-invasive version of PRF. It has shown promising results in animal studies and in clinical research for knee and shoulder conditions, but has not been tested for CR. Recent improvements in ultrasound allow more precise targeting of cervical nerve roots, making ultrasound-guided TCPRF a potentially safe and accessible treatment option.\n\nThis pilot study will evaluate the efficacy and safety of ultrasound-guided TCPRF in patients with CR compared to a sham treatment. A total of 32 participants with CR lasting more than six weeks will be randomly assigned to either TCPRF or sham treatment. Both groups will receive 12 treatment sessions over four weeks, combined with a standard rehabilitation program.\n\nThe main outcome is pain intensity measured by the Numeric Rating Scale (NRS). Secondary outcomes include neck-related disability, medication use, and any side effects.",[27],"Cervical Radiculopathy",[29,30,31,32],"cervical radiculopathy","pulsed radiofrequency","transcutaneous pulsed radiofrequency","ultrasound guided","RECRUITING","2026-05-08",{"date":36,"type":37},"2026-05-13","ACTUAL",{"date":39,"type":37},"2025-11-01",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Shin Kong Wu Ho-Su Memorial Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100617852","efficacy-of-combining-ultrasound-guided-needle-release-of-transverse-carpal-ligament-and-median-nerve-dextrose-water-hydrodissection-for-carpal-tunnel-syndrome-100617852","NCT07324005","Efficacy of Combining Ultrasound-Guided Needle Release of Transverse Carpal Ligament and Median Nerve Dextrose Water Hydrodissection for Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* age between 20 to 80 years old\n* diagnosed with CTS on the basis of clinical condition and an electrophysiological analysis\n* the NRS of pain or paresthesia≧3\n* with symptoms lasting for a minimum of 3 months.\n\nExclusion Criteria:\n\n* history of polyneuropathy, thoracic outlet syndrome, brachial plexopathy, or inflammatory arthropathy\n* onset of CTS during pregnancy, hypothyroidism, or systemic infection\n* previous corticosteroid injection or wrist surgery for CTS\n* hypersensitivity to dextrose injection\n* the anatomic structure of the wrist is not suitable for needle release of TCL.","80 Years",{"count":54,"type":21},102,[24],"Carpal tunnel syndrome (CTS) is a common musculoskeletal disorder, which is caused by compression of the median nerve as it travels through the wrist. There are several treatments for CTS, including conservative and surgical options. Though local corticosteroid injection has been considered more effective than physical therapy for treatment of CTS and has significant short-term benefits, long term benefits are not evidenced. Several studies in recent years reported significantly superior longer-term benefit of D5W and PRP compared with corticosteroid injections and other conservative managements. In addition, percutaneous release of the transverse carpal ligament (TCL) was developed to treat CTS in recent years. Because the effectiveness of the recently developed techniques in treating CTS has not been well established, the investigators aim to investigate whether combining US-guided partial release of the transverse carpal ligament with a needle plus D5W hydrodissection is more beneficial for CTS comparing to either treatment alone.",[58,59,60,61,62],"Carpal Tunnel Syndrome","Dextrose","Carpal Tunnel Release","Ultrasound","Nerve Hydrodissection Therapy",[58,64,65,66,67],"dextrose","carpal tunnel release","ultrasound","nerve hydrodissection therapy","2026-04-21",{"date":70,"type":37},"2026-04-23",{"date":72,"type":37},"2026-01-01",{"date":74,"type":21},"2030-12-31",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":52,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100574162","comparative-efficacy-of-intra-articular-vs-mri-guided-extra-articular-dextrose-injections-in-knee-osteoarthritis-management-100574162","NCT06755697","Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management","Inclusion Criteria:\n\n1. . age between 45 to 80 years old;\n2. . meet at least three of the six American College of Rheumatology (ACR) criteria, including age over 50 years, morning stiffness less than 30 minutes, crepitus in passive knee movements, bony tenderness, bony enlargement, and no palpable warmth;\n3. . radiologic grading of 2 or 3 according to Kellgren-Lawrence criteria;\n4. showing willingness to receive prolotherapy.\n\nExclusion Criteria:\n\n1. . severe systemic disorders including cancer, uncontrolled diabetes mellitus, sepsis, or cardiopulmonary diseases;\n2. . history of anticoagulation therapy, knee injection over the past three months;\n3. . history of knee surgery or candidates for knee arthroplasty;\n4. . history of drug abuse;\n5. . a history of intolerance to prolotherapy;\n6. . pregnancy;\n7. . infectious arthritis, inflammatory joint diseases, joint dysplasia;\n8. Body Mass Index (BMI) greater than 35 kg\u002Fm2;\n9. . not suitable or no willing to received MRI examination of the knee.","45 Years",{"count":84,"type":21},60,[24],"Osteoarthritis (OA) is a serious worldwide public health concern, causing increased disability-adjusted life years (DALY), the reasons of which include rising prevalence of obesity and increasing older populations. The knee is one of the most easily injured joint in the body, and knee OA can become a chronic and disabling condition that pose a threat to not only the patient but also his or her caretakers and healthcare resources. The prevalence of knee OA is 5% - 15% in men over 60 years, and 10% - 25% in women aged more than 60.\n\nKnee OA can result from injuries, diseases, or wear and tear from overuse. It refers to structural changes that affect subchondral bone, articular cartilage, menisci, ligaments, synovium, and other joint structures. Currently, there are several conservative management of knee OA, including physiotherapy (therapeutic exercise, diathermy, electrotherapy), oral or topical medications, intra-articular and extra-articular injections, and radiofrequency.\n\nThere are various substances used in injections for knee OA, among which are corticosteroid, platelet-rich plasma (PRP), AmnioFix, exosome, dextrose, and hyaluronic acid (HA). Compared with PRP, AmnioFix, exosome, and HA, which are not covered by the health insurance system, dextrose is a readily available and cost-effective substance. The principle of hypertonic dextrose injection, \"prolotherapy\", is injection of small volumes of the irritant solution at or around the lesion in order to stimulate fibroblast and vascular proliferation, local tissue healing, reduction of joint instability, thus resulting in pain relief. Previous studies have demonstrated that prolotherapy resulted in clinically meaningful sustained improvement of function and pain in knee OA, and there were no severe adverse events related to hypertonic dextrose injection. A study in 2023 showed that among various dextrose concentrations, higher concentrations demonstrated greater improvement of knee OA, thus 20% dextrose is recommended.\n\nRegarding the site of dextrose injection in knee OA, previous studies demonstrated comparable effects of intra-articular and extra-articular injections. The periarticular injections include points around the knee where periarticular nerves exit the joint capsule, and acupuncture points at upper medial and lateral parts of knee joint. A study in 2024 revealed that prolotherapy combining intra-articular with peri-articular perineural injection resulted in better pain alleviation and improvement in knee joint function in knee OA. There are several choices of imaging modality for recognizing the sites of lesion in knee OA, such as X-ray, ultrasound (US), and magnetic resonance imaging (MRI). Radiography is used to assess osteophytes, joint space narrowing, and subchondral sclerosis, but it has limited ability to detect synovial inflammation, joint effusion, soft tissue abnormalities, and early cartilage damage. US can be used to evaluate synovial fluid and cartilage thickness, but not deep structures (e.g. subchondral bone change, meniscus tear, and ACL tear, etc.). On the other hand, MRI is an optimal and accurate imaging choice for visualizing soft tissue as well as deep structures (e.g. ACL, meniscus, etc) in knee OA. The MRI findings of knee OA includes cartilage damage, meniscus tear, bone marrow lesions, synovitis, ligamentous laxity, and osteophytes. The detection of bony lesions can aid intraosseous Infiltrations, and signs of ligamentous laxity also provides target for ligaments injection. However, there is no current evidence on the effectiveness of prolotherapy targeting knee OA lesion sites according to MRI findings.\n\nBecause the effectiveness of prolotherapy targeting lesion sites according to MRI findings has not been well established, the investigators aim to investigate whether injecting dextrose into MRI-positive lesion sites is more beneficial for knee OA comparing to intra-articular injections. The investigators hypothesize that MRI could be a good choice for the guidance of prolotherapy targets.",[88,89,90,91,92,93],"Knee Osteoarthritis","Glucose","Prolotherapy","MRI","Physical Therapy","Rehabilitation",{"date":95,"type":37},"2026-04-24",{"date":97,"type":37},"2025-01-23",{"date":99,"type":21},"2028-12-31",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100570038","the-efficacy-of-transcutaneous-pulsed-radiofrequency-acupuncture-for-knee-osteoarthritis-100570038","NCT06702046","The Efficacy of Transcutaneous Pulsed Radiofrequency Acupuncture for Knee Osteoarthritis","Inclusion Criteria:\n\n* Age from 45 to 85 year-old with knee pain for more than six months\n* Fulfill the combined clinical and radiographic criteria of knee OA established by the American College of Rheumatology with a Kellgren and Lawrence score of 2 or greater\n* Pain score above 3 (range 0-10 on the visual analog scale; higher scores indicate greater pain\n* Could participate in 4 weeks of treatment and 3 months of follow-up\n\nExclusion Criteria:\n\n* Knee OA combined with any infection, inflammation, autoimmune disease, or fracture\n* History or underlying disease that would affect posture and balance, such as malignancy, dizziness, vertigo, or stroke\n* Ever underwent any type of knee operation or internal fixation\n* Pregnant or planning to become pregnant\n* Receiving other treatment for knee OA in previous 3 months\n* History of epilepsy, electronic devices implanted in the body\n* Active infection at the stimulator contact site\n* Lack of informed consent\n* Any other reason thought likely to result in inability to complete the trial","85 Years",{"count":109,"type":21},90,[24],"Efficacy of transcutaneous acupoint pulsed radiofrequency with rehabilitation for knee osteoarthritis.",[113],"Osteoarthritis (OA) of the Knee",[115,31,116,117],"knee osteoarthritis","acupuncture","acupoints",{"date":95,"type":37},{"date":120,"type":37},"2025-02-24",{"date":122,"type":21},"2028-06-30",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100634183","phase-3-colchicine-in-chronic-limb-threatening-ischemia-100634183","NCT07536373","Colchicine in Chronic Limb-Threatening Ischemia","Colchicine in Chronic Limb-Threatening Ischemia for Reduction of Complications and Limb Events in Asia","CIRCLE-Asia","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Documented chronic limb-threatening ischemia, meeting the following:\n\n   * Presence of ischemic symptoms compatible with CLTI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford classes 4-5 AND\n   * Imaging evidence within the past 12 months showing atherosclerotic PAD, including CTA, MRA, angiography or duplex ultrasound AND\n   * Ankle-Brachial Index (ABI) ≤0.80 or Toe-Brachial Index (TBI) ≤0.60 for patients without prior revascularization; ABI ≤0.85 or TBI ≤0.65 for those with prior revascularization OR\n   * Ischemic rest pain alone (Rutherford class 4) defined as ankle systolic pressure \\\u003C50 mmHg, toe pressure of \\\u003C30 mmHg, transcutaneous PO2 of \\\u003C30 mmHg, or flat-line transtarsal pulse volume recording OR\n   * Tissue loss with or without ischemic rest pain (Rutherford class 5) defined as ankle systolic pressure \\\u003C70 mmHg, toe pressure of \\\u003C50 mmHg, transcutaneous PO2 of \\\u003C30 mmHg, or flatline transtarsal pulse volume recording\n3. Recent successful revascularization:\n\n   * Underwent technically successful endovascular therapy (EVT) or surgical bypass within the last 7 days prior to randomization\n   * For individuals requiring multiple revascularization attempts on the same index leg, the procedure considered for eligibility (in other words, the qualifying or index procedure) must be the final planned or anticipated revascularization attempt\n   * There must be demonstrated graft or vascular patency after the qualifying revascularization procedure with one in-line blood flow to the foot, either by angiography, duplex ultrasound, CTA or MRA\n   * There must be no immediate plan for reintervention\n4. Informed Consent:\n\n   * Demonstrated ability and willingness to adhere to the study protocol, attend scheduled follow-up visits, complete all required assessments, and provide written informed consent\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Asymptomatic or mild disease: Patients who underwent revascularization for disease graded Rutherford classes 0-3\n3. Patients with major tissue loss (Rutherford 6) in whom major amputation was planned at the time of screening\n4. Failure to establish at least one tibial artery outflow after revascularization\n5. Recent acute limb ischemia events within 2 weeks of screening\n6. Clinical signs of active, uncontrolled, severe limb infection or septicemia, such as fever exceeding 38.5°C, a white blood cell count above 15,000 cells\u002FµL, or hypotension, at the time of screening (this does not include osteomyelitis confined to the phalanges or metatarsal heads or foot cellulitis treatable with IV antibiotics at the time of revascularization)\n7. Unstable hemodynamics after the index revascularization procedure\n8. Unable to tolerate any antiplatelet agent or with severe bleeding diathesis\n9. Acute coronary syndrome, acute stroke, or hospitalization for heart failure within 30 days of screening\n10. Any contraindication or known intolerance to colchicine\n11. Requirement for colchicine for another indication\n12. Need for use of medications known to have drug-drug interactions with colchicine, particularly drugs known to inhibit CYP3A4 or P-glycoprotein\n13. Active hepatitis or severe liver cirrhosis (Child Pugh C)\n14. Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception\n15. Previous (within 30 days) or concomitant participation in another clinical study with investigational medicinal product(s)\n16. Life expectancy \\\u003C1 year","18 Years",{"count":134,"type":21},200,[136],"PHASE3","Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease, a condition in which narrowed or blocked arteries reduce blood flow to the legs. People with CLTI may have severe leg pain at rest, non-healing wounds, or gangrene, and face a high risk of leg amputation and death. Even after successful procedures to restore blood flow to the leg (called revascularization), many patients still experience serious complications. Inflammation in the blood vessels is believed to play an important role in these poor outcomes.\n\nColchicine is an anti-inflammatory medication that has been used safely for decades to treat gout and other inflammatory conditions. Recent large clinical trials have shown that a low dose of colchicine (0.5 mg per day) can reduce heart attacks and strokes in patients with coronary artery disease. However, it has not been studied in patients with CLTI.\n\nThe CIRCLE-Asia trial (Colchicine in Chronic Limb-Threatening Ischemia for Reduction of Complications and Limb Events in Asia) is a pilot study designed to evaluate whether colchicine can improve outcomes in patients with CLTI who have recently undergone a successful procedure to restore blood flow to their leg. Treatment begins within 7 days of the procedure.\n\nThis is a randomized, double-blind, placebo-controlled, multicenter trial conducted at five hospitals in Taiwan. A total of 200 adult patients with CLTI who have undergone successful revascularization will be randomly assigned in a 1:1 ratio to receive either colchicine 0.5 mg once daily or a matching placebo pill, in addition to their usual medications, for 12 months. Neither the patients nor the study doctors will know which treatment each patient receives.\n\nThe main outcome of interest is amputation-free survival, defined as the time until major amputation of the affected leg (above the ankle) or death from any cause, over 12 months of follow-up. The study will also assess other important outcomes including major limb complications, heart attacks, strokes, wound healing, changes in blood flow measurements, inflammatory blood markers, quality of life, and medication safety.\n\nThis pilot trial will provide the first randomized evidence on the potential benefits and safety of colchicine in CLTI patients and will help inform the design of a larger definitive trial.",[139],"Chronic Limb-Threatening Ischemia",[130,141,142,143,144],"Chronic limb-threatening ischemia","Peripheral artery disease","Colchicine","Amputation-free survival","NOT_YET_RECRUITING","2026-04-11",{"date":148,"type":37},"2026-04-17",{"date":150,"type":21},"2026-04-15",{"date":152,"type":21},"2030-04",{"name":43,"class":44},5,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":45},"100553873","is-adding-extracorporeal-shock-wave-therapy-to-physiotherapy-and-corticosteroid-injection-beneficial-for-frozen-shoulder-100553873","NCT06491745","Is Adding Extracorporeal Shock Wave Therapy to Physiotherapy and Corticosteroid Injection Beneficial for Frozen Shoulder","Is Adding Extracorporeal Shock Wave Therapy to Physiotherapy and Corticosteroid Injection Beneficial for Frozen Shoulder?","Inclusion Criteria:\n\n1. age between 20 to 80 years old;\n2. shoulder pain for ≥ 1 month;\n3. \\> 30% loss of passive range of motion (ROM) of the affected shoulder in external rotation and\u002For abduction, comparing with the sound side;\n4. pain visual analog scale on maximal passive external rotation or abduction \\> 4;\n5. showing willing to receive ESWT, shoulder joint injection, and attend regular physical therapy programs for 8 weeks.\n\nExclusion Criteria:\n\n1. severe systemic disorders including cancer, stroke, or cardiopulmonary diseases;\n2. uncontrolled DM;\n3. rotator cuff tear or calcification of the affected shoulder;\n4. fracture, dislocation, or arthritis of the shoulder due to rheumatic disorders;\n5. a history of drug allergy to local anesthetics or corticosteroids;\n6. pregnancy;\n7. receiving ESWT, corticosteroid joint or bursa injection of the affected shoulder during the preceding three months",{"count":163,"type":21},94,[24],"Frozen shoulder, or adhesive capsulitis of the shoulder, is a common clinical problem characterized by pain, loss of both passive and active range of motion (ROM) of glenohumeral joint (GHJ), leads to functional limitation, and reduces quality of life. Primary frozen shoulder occurs without any obvious connection to any other condition, and secondary frozen shoulder is related to some medical problems, such as an injury, inflammatory, immunological, and endocrine conditions, or surgery of the shoulder. The prevalence of frozen shoulder is 2%-5% in general population, usually between 40 to 60 years old, and more in female. Diabetes patients have more chance of developing frozen shoulder than general population and the prevalence was 13.4%.\n\nFrozen shoulder is clinically divided into 3 overlapping phases. The painful freezing phase has a duration of 10 to 36 weeks and is characterized by pain and stiffness around the shoulder, which may worsen at night. The frozen phase is characterized by restricted ROM with a gradual relief of pain, which occurs at 4 to 12 months. The thawing phase with spontaneous improvement in the ROM takes 12 to 42 months. .Although frozen shoulder is a self-limited condition, the recovery may be slow and incomplete.\n\nTreatment of frozen shoulder consists of physiotherapy, oral medication (nonsteroidal anti-inflammatory drugs or corticosteroid), intra-articular corticosteroid injection, hydrodilatation, suprascapular nerve block, mobilization, manipulation under anesthesia, and operative intervention (arthroscopic release or open release). Because of the uncertainty of the efficacy and risk of surgical treatment, nonsurgical treatments are more likely chosen by patients. Among them, intra-articular steroid injection and physical therapy are commonly used nonsurgical treatments and have shown some benefits. .Because the clinical picture of frozen shoulder may be similar to, or combining with chronic subacromial bursitis, especially in the freezing stage, concomitant subacromial\u002Fsubdeltoid (SASD) bursa injection may be needed for treatment of frozen shoulder. In addition, the 3 stages of frozen shoulder often overlap and the clinical symptoms of patients are complex, adjuvant therapy is often needed throughout the course of treatment. Even after physical therapy (PT) and corticosteroid injection, mild to moderate contracture, especially external rotation, abduction, and internal rotation may still be present.\n\nOver the past few years new evidence has emerged on the effectiveness of extracorporeal shock wave therapy (ESWT) in the treatment of many musculoskeletal disorders. Briefly, ESWT has been shown to promote neovasculization, amplify growth factor and protein synthesis, increase of pain inhibiting substance, alteration of pain receptor neurotransmission, and intensification of tissue regeneration. Furthermore, ESWT can produce a cavitation effect between tissues, cause intertissue release, promote the separation of adhesion, and release the adhesive tissue. Because of its analgesic, anti-fibrotic, and anti-inflammatory effect, application of ESWT as main treatment or an adjunct to other interventions has been tried. Knoblock et al found that focused ESWT can reduce pain in painful nodules in Dupuytren's disease; in a randomized controlled trial Chen et al showed focused ESWT was superior to oral corticosteroid for frozen shoulder, although oral corticosteroid is not commonly prescribed for patients with frozen shoulder. Vahdatpour compared ESWT with sham ESWT on treatment of frozen shoulder after 40mg triamcinolone intra-articular injection, and found that ESWT group seemed to have positive effects on treatment, and quicker return to daily life. Another two studies investigating application of radial shock wave to patients with frozen shoulder showed improvement of ROM, even for diabetic patients. A systemic review and meta-analysis also showed ESWT seems beneficial to patients with frozen shoulder and could be used as an adjunct therapy to routine treatments. However, the authors mentioned that the quality of the included randomized controlled trials were hampered by significant heterogeneity regarding long-term analgesia and joint ROM.\n\nBecause the effect of ESWT against frozen shoulder has not been well established, we aim to investigate whether adding ESWT to corticosteroid injection and routine PT beneficial for patients with frozen shoulder? We hypothesize that ESWT would be a positive adjunctive therapy in the treatment of frozen shoulder.",[167,168,92,169,93],"Frozen Shoulder","Corticosteroid Injection","Extracorporeal Shock Wave Therapy",[171,172,173,174,175],"Frozen shoulder","corticosteroid injection","physical therapy","extracorporeal shock wave therapy","rehabilitation","2025-12-22",{"date":178,"type":37},"2025-12-30",{"date":180,"type":37},"2024-08-01",{"date":99,"type":21},{"name":43,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":45},"100595407","continuous-passive-motion-to-prevent-ankle-contracture-and-muscle-atrophy-in-ventilated-patients-100595407","NCT07032051","Continuous Passive Motion to Prevent Ankle Contracture and Muscle Atrophy in Ventilated Patients","Preventive Effects of Continuous Passive Motion on Ankle Contracture and Muscle Atrophy in Mechanically Ventilated Patients: A Pilot Study","CPM-ICU","Inclusion Criteria:\n\n\\- Eligible participants were adults (≥18 years) with acute respiratory failure expected to require mechanical ventilation for \\>5 days.\n\nExclusion Criteria:\n\n* Neuromuscular disorders\n* Recent lower limb surgery or trauma\n* Critical limb ischemia\n* Limb amputation\n* Deep vein thrombosis\n* Significant leg wounds\n* Pregnancy.",{"count":192,"type":21},20,[24],"This clinical trial aims to evaluate whether continuous passive motion (CPM) can prevent ankle joint contracture and muscle atrophy in critically ill patients receiving mechanical ventilation in the ICU. The study will also assess the feasibility and safety of implementing CPM therapy in this population.\n\nThe primary objectives are:\n\nTo determine whether CPM preserves ankle dorsiflexion range of motion during ICU immobilization.\n\nTo assess whether ultrasound can detect changes in tibialis anterior muscle morphology in response to CPM.\n\nIn this within-subject design, each participant will receive CPM therapy on one ankle while the contralateral ankle serves as the control. Outcomes related to joint mobility and muscle condition will be compared between the two sides.\n\nParticipants will:\n\nReceive CPM treatment on one ankle for 30 minutes, twice daily, for up to 7 days or until ICU discharge.\n\nUndergo goniometric and ultrasound assessments at baseline and after the intervention.\n\nContinue to receive standard ICU care throughout the study period.",[196,197,198],"Ankle Contracture","Critically Ill Intensive Care Unit Patients","Muscle Atrophy",[200,201,202,203],"ICU-acquired weakness","muscle ultrasound","ankle contracture","continuous passive motion,","2025-06-26",{"date":206,"type":37},"2025-06-29",{"date":208,"type":21},"2025-06-25",{"date":210,"type":21},"2025-12-31",{"name":43,"class":44},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100588014","phase-4-additional-effect-of-steroid-on-hyaluronic-acid-in-subdeltoid-bursitis-100588014","NCT06935877","Additional Effect of Steroid on Hyaluronic Acid in Subdeltoid Bursitis","Comparison of the Efficacy of Combined Hyaluronic Acid and Triamcinolone Acetonide Injection and Hyaluronic Acid Alone Injection in Patients With Subdeltoid Bursitis","Inclusion Criteria:\n\n* \\- Unilateral shoulder pain within the past 3 months\n\nPain during joint movements such as abduction or internal rotation\n\nAt least one positive result from the following tests: Painful arc, Neer test, or Hawkins test\n\nNo shoulder injections received in the past 3 months\n\nWillingness to receive injection treatment and undergo follow-up assessments at the following time points:\n\nImmediate (1 week after injection)\n\nShort-term (1 month after injection)\n\nMid-term (3 months after injection)\n\nAvoid use of anti-inflammatory painkillers during the study period as much as possible; if intolerable pain occurs, acetaminophen (provided by the researcher) will be used to relieve symptoms\n\nExclusion Criteria:\n\n* Presence of infectious disease, inflammation, rheumatoid arthritis, or fracture\n\nHistory of malignancy\n\nPrevious shoulder surgery\n\nSensory deficits\n\nTendon rupture of the rotator cuff or biceps tendon\n\nNeurological disorders causing hand weakness or affecting shoulder mobility (e.g., stroke, Parkinson's disease, brachial plexus injury, peripheral neuropathy)\n\nCognitive impairment preventing completion of questionnaires\n\nCervical radiculopathy\n\nDiagnosed frozen shoulder (adhesive capsulitis)\n\nPsychiatric disorders\n\nBreastfeeding or pregnant women\n\nReceived shoulder injection within the past 3 months, including corticosteroids, hyaluronic acid, Platelet-rich plasma, or any prolotherapy solution",{"count":84,"type":21},[221],"PHASE4","The study employs a double-blind, randomized clinical trial design with 60 patients diagnosed with subdeltoid bursitis. Participants are divided into two groups: the experimental group receives combined hyaluronic acid and Triamcinolone Acetonide injections, while the control group receives hyaluronic acid alone injection. All injections are guided by ultrasound. Assessments are conducted before treatment and at 1 week, 1 month, and 3 months post-treatment.",[224],"Subdeltoid Bursitis of the Shoulder","2025-04-20",{"date":227,"type":37},"2025-04-24",{"date":229,"type":21},"2025-04-25",{"date":231,"type":21},"2026-06-30",{"name":43,"class":44},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":52,"enrollmentInfo":240,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":45},"100533338","pulse-wave-velocity-and-in-subacute-stroke-patients-following-rehabilitation-100533338","NCT06224517","Pulse Wave Velocity and in Subacute Stroke Patients Following Rehabilitation","The Improvement in Pulse Wave Velocity and Its Correlation With Clinical Outcomes in Subacute Stroke Patients Following Rehabilitation","Inclusion Criteria:\n\n* First-onset cerebral ischemic stroke within the previous 3 months, which is confirmed clinically by computed tomography scans or magnetic resonance imaging\n* Sufficient cognition to understand procedures and provide informed consent.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke, cerebellar or brainstem lesions which may affect autonomic or balance\n* Concurrent neurological or neurodegenerative diseases (e.g. Parkinson's disease, multiple sclerosis, etc.)\n* Brain tumor\n* Malignancy\n* Limb deficiency or amputation",{"count":241,"type":21},25,"OBSERVATIONAL","Currently, the literature regarding the relationship between Pulse Wave Velocity (PWV) and functional recovery, particularly of upper limb function, in patients with subacute stroke is still limited. Therefore, the aim of the study is to evaluate the changes in baPWV after four weeks of intensive rehabilitation therapy, and the correlation between these changes and functional recovery.",[245,246,247,93],"Ischemic Stroke","Arterial Stiffness","Pulse Wave Velocity",[249,246,250,175],"ischemic stroke","pulse wave velocity","2025-02-23",{"date":253,"type":37},"2025-02-25",{"date":255,"type":37},"2024-02-01",{"date":257,"type":21},"2025-06-30",{"name":43,"class":44},""]